Literature DB >> 14749545

Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.

A Rousseau1, F Léger, Y Le Meur, F Saint-Marcoux, G Paintaud, M Buchler, P Marquet.   

Abstract

There have been very few population pharmacokinetic (PopPK) studies and Bayesian forecasting methods dealing with cyclosporin (CsA) so far, probably because of the difficulty of modeling the particular absorption profiles of CsA. The present study was conducted in stable renal transplant patients treated with Neoral and employed the NONMEM program. Its goals were (1) to develop a population pharmacokinetic model for CsA based on an Erlang frequency distribution (which describes asymmetric S-shaped absorption profiles) combined with a 2-compartment model; (2) to compare this model with models combining a time-lag parameter and either a zero-order or first-order rate constant and with a model based on a Weibull distribution; and (3) to develop a PK Bayesian estimator for full AUC estimation based on that "Erlang model." The PopPK model was developed in an index set of 70 patients, and then individual PK parameters and AUC were estimated in 10 other patients using Bayesian estimation. The "Erlang" model best described the data, with mean absorption time (MAT), apparent clearance (CL/F), and apparent volume of the central compartment (Vc/F) of 0.78 hours, 26.3 L/h, and 76 L, respectively (interindividual variability CV = 33, 30, and 48%). Bayesian estimation allowed accurate prediction of systemic exposure using only 3 samples collected at 0, 1, and 3 hours. Regression analysis found no significant difference between the predicted and observed concentrations (10 per patient), and AUC(0-12) were estimated with a nonsignificant bias (0.6 to 8.7%) and good precision (RMSE = 5.3%). In conclusion, the Erlang distribution best described CsA absorption profiles, and a Bayesian estimator developed using this model and a mixed-effect PK modeling program provided accurate estimates of CsA systemic exposure using only 3 blood samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749545     DOI: 10.1097/00007691-200402000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  43 in total

1.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

2.  Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.

Authors:  Jean-Baptiste Woillard; Brenda C M de Winter; Nassim Kamar; Pierre Marquet; Lionel Rostaing; Annick Rousseau
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

4.  A simple absorption model for dose-escalating studies.

Authors:  Anders Källén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-02-07       Impact factor: 2.745

Review 5.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

7.  Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.

Authors:  Ling Xue; Wen-Juan Zhang; Ji-Xin Tian; Lin-Na Liu; Hai-Hong Yan; Wen-Wen Zhang; Xiao-Liang Ding; Jing-Jing Zhang; Li-Yan Miao
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

8.  Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.

Authors:  Hee-Doo Yoo; Mi-Suk Kim; Hea-Young Cho; Yong-Bok Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-04-08       Impact factor: 2.953

9.  Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients.

Authors:  A Thorsted; P Thygesen; H Agersø; T Laursen; M Kreilgaard
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

10.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.